Tolinapant

N/A

Report date: 2026/03/21 20:00:21
NME

Base Information

Drug NameTolinapant
Drug Alias NameASTX-660
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of apoptosis protein 3 inhibitorsCellular inhibitor of apoptosis protein 1 inhibitors
TargetsInhibitor of apoptosis protein 3Cellular inhibitor of apoptosis protein 1
Therapy Area/IndicationsSolid tumoursHR-positive breast cancerUterine Cervical Neoplasms +[21] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEmory UniversityAstex Pharmaceuticals IncThe Institute Of Cancer Research, London +[4] 
Inactive CompaniesNational Cancer InstituteOtsuka Pharmaceutical Co Ltd
Active IndicationsSolid tumoursUterine Cervical NeoplasmsNasopharyngeal Neoplasms +[9] 
Inactive IndicationsHR-positive breast cancerEndometrial NeoplasmsFallopian Tube Neoplasms +[12] 

Other Information

ATC CodeN/A
Related LinksN/A